Cross protection against HPV might prevent type replacement

Verdenius, Inge; Groner, Jennifer A.; Harper, Diane M.

doi:10.1016/s1473-3099(13)70024-0

Cited by 8 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly however, a recent study suggests reduced HPV‐driven carcinogenesis in cases of coinfection with oncogenic HPV types from the same papillomavirus species among HIV‐infected patients . This was interpreted as an evidence of natural cross‐protection against HPV‐induced carcinogenesis by multiple HPV infections from the same HPV species group . Nonetheless, we did observe that HPVs coinfection prevalence was consistently about three‐fold higher in ICCs from Africa compared to the rest of the world.…”

Section: Discussioncontrasting

confidence: 55%

“…33 This was interpreted as an evidence of natural cross-protection against HPV-induced carcinogenesis by multiple HPV infections from the same HPV species group. 22,33,34 Nonetheless, we did observe that HPVs coinfection prevalence was consistently about three-fold higher in ICCs from Africa compared to the rest of the world. One explanation could be concomitant HIV infection which may increase the prevalence of multiple HPVs coinfections.…”

Section: Hpvs Coinfection Prevalencementioning

confidence: 53%

“…Our study and all protocols were approved by both local and ICO ethics committees. After pathological confirmation of primary ICC, HPV DNA detection was performed by PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay (DEIA) and genotyping with a reverse hybridization line probe assay (LiPA25 SPF10-PCR)-LIPA25 that detects 25 HPV types (HPV6, 11,16,18,31,33,34,35,39,40,42,43,44,45,51,52,53,54,56,58,66,68, 70, and 74) (see details in Ref. 5 ).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide cross‐sectional study

Pimenoff

Tous

Benavente

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

Coinfections by multiple Human Papillomaviruses (HPVs) are observed in approximately 6–8% of invasive cervical cancer (ICC) cases worldwide. But neither the presence of persistent HPVs coinfections nor their etiological role in the development of ICC is well understood. Cervical HPVs coinfections have been observed randomly, mostly in women with preneoplastic lesions, and only few studies have globally analyzed ICC cases. Here we explored the HPVs multiple infection patterns in a large worldwide sample of cross‐sectional ICC cases. Paraffin‐embedded ICC biopsy samples were tested using stringent HPV genotyping. Logistic regression models were used to identify the most likely pairwise HPV types in multiple infections. Multivariate analysis was applied to detect significant HPV coinfection patterns beyond pairwise HPVs comparison. Among 8780 HPV DNA‐positive ICC cases worldwide, 6.7% (N = 587) contained multiple HPVs. Pairwise analysis revealed that HPV16|74, HPV31|33, HPV31|44, HPV33|44 and HPV45|70 pairs were significantly more frequently found together in multiple infections compared to any other HPV type combination, which supports the occasional role of Alpha‐10 LR‐HPVs in cervical cancers. In contrast, HPV16|31, HPV16|45, HPV16|51 and HPV18|HPV45 pairs were significantly less frequently found together than with any other HPV pair combination. Multivariate analysis sustained the results and revealed for the first time a distinct coinfection pattern in African ICCs stemming from the clustering of oncogenic HPV51/35/18/52 coinfections in African women. We suggest that the differential geographic HPVs coinfections clustering observed might be compatible with a specific modulation of the natural history/oncogenic potential of particular HPVs multiple infections and warrant monitoring for post‐vaccinated.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Hpvs Coinfection Prevalencementioning

confidence: 53%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide cross‐sectional study

Pimenoff

Tous

Benavente

et al. 2018

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Therefore the HPV genotypes covered by the current HPV vaccination programme will lower the prevalence of HPV 16/18, as has already been evidenced in Scotland [Kavanagh et al, ], and should prevent the majority of cervical cancers in NI. The formerly used bivalent vaccine (Cervarix ® ) offers some cross‐protection for HPV genotypes of the A7 species including HR HPV‐31, 33 and 45 [Paavonen et al, ; Malagón et al, ; de Vincenzo et al, ; Verdenius et al, ]. The potential effects of vaccine cross protection against other oncogenic non‐target genotypes should also be considered when conducting future cost‐benefit analyses.…”

Section: Discussionmentioning

confidence: 99%

HPV prevalence and type‐distribution in cervical cancer and premalignant lesions of the cervix: A population‐based study from Northern Ireland

Anderson¹,

O’Rorke²,

Wilson

et al. 2016

Journal of Medical Virology

View full text Add to dashboard Cite

Assessment of Human papillomavirus (HPV) prevalence and genotype distribution is important for monitoring the impact of prophylactic HPV vaccination. This study aimed to demonstrate the HPV genotypes predominating in pre‐malignant and cervical cancers in Northern Ireland (NI) before the vaccination campaign has effect. Formalin fixed paraffin embedded tissue blocks from 2,303 women aged 16–93 years throughout NI were collated between April 2011 and February 2013. HPV DNA was amplified by PCR and HPV genotyping undertaken using the Roche® linear array detection kit. In total, 1,241 out of 1,830 eligible samples (68.0%) tested positive for HPV, with the majority of these [1,181/1,830 (64.5%)] having high‐risk (HR) HPV infection; 37.4% were positive for HPV‐16 (n = 684) and 5.1% for HPV‐18 (n = 93). HPV type‐specific prevalence was 48.1%, 65.9%, 81.3%, 92.2%, and 64.3% among cervical intraepithelial neoplasias (CIN) Grades I–III, squamous cell carcinomas (SCC) and adenocarcinoma (AC) cases, respectively. Most SCC cases (81.3%) had only one HPV genotype detected and almost a third (32.0%) of all cervical pathologies were HPV negative including 51.9% of CIN I (n = 283), 34.1% CIN II (n = 145), 18.7% of CIN III (n = 146), 7.8% of SCC (n = 5), and 35.7% of AC (n = 5) cases. This study provides important baseline data for monitoring the effect of HPV vaccination in NI and for comparison with other UK regions. The coverage of other HR‐HPV genotypes apart from 16 and 18, including HPV‐45, 31, 39, and 52, and the potential for cross protection, should be considered when considering future polyvalent vaccines. J. Med. Virol. 88:1262–1270, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

“…On the other hand, cross protection of the vaccine may somewhat mitigate against type replacement, particularly against 31, 33 & 45. There is some evidence suggesting that Cervarix® may confer relatively high levels of cross-protection [22]. …”

Section: Discussionmentioning

confidence: 99%

Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact

et al. 2013

View full text Add to dashboard Cite

BackgroundEstimation of pre-immunisation prevalence of HPV and distribution of HPV types is fundamental to understanding the subsequent impact of HPV vaccination. We describe the type specific prevalence of HPV in females aged 20–21 in Scotland who attended or defaulted from cervical screening using three specimen types; from attenders liquid based cytology and from defaulters urine or self-taken swabs.MethodsResidual liquid based cytology samples (n = 2148), collected from women aged 20–21 attending for their first smear were genotyped for HPV. A sample (n = 709) from women who had defaulted from screening was also made available for HPV testing through the use of postal testing kits (either urine samples (n = 378) or self-taken swabs (n = 331)). Estimates of prevalence weighted by deprivation, and for the postal testing kit, also by reminder status and specimen type were calculated for each HPV type. The distribution of HPV types were compared between specimen types and the occurrence of multiple high-risk infections examined. The influence of demographic factors on high-risk HPV positivity and multiple infections was examined via logistic regression.ResultsThe prevalence of any HPV in young women aged 20–21 was 32.2% for urine, 39.5% for self-taken swab, and 49.4% for LBC specimens. Infection with vaccine specific types (HPV 16, 18) or those associated with cross-protection (HPV 31, 33, 45, 51) was common. Individuals were more likely to test positive for high-risk HPV if they resided in an area of high deprivation or in a rural area. The overall distribution of HPV types did not vary between defaulters and attenders. Multiple infections occurred in 48.1% of high-risk HPV positive individuals. Excluding vaccine types the most common pairing was HPV 56 and 66.ConclusionsUnderstanding of the pre-immunisation prevalence of HPV in young women puts Scotland in a prime position to assess the early effect of vaccination as the first highly vaccinated cohorts of individuals enter the screening programme. Differences in results with different specimen types must be taken into account when monitoring the impact of vaccination programmes.

show abstract

Cross protection against HPV might prevent type replacement

Cited by 8 publications

References 5 publications

Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide cross‐sectional study

Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: Results from a worldwide cross‐sectional study

HPV prevalence and type‐distribution in cervical cancer and premalignant lesions of the cervix: A population‐based study from Northern Ireland

Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact

Contact Info

Product

Resources

About